Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Clinical trial NCT05325632 · RECRUITING

Trial details

NCT number: NCT05325632
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2021-10-28
Primary completion: 2027-02-01
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.